ArticleArchives of gynecology and obstetrics2026
Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité.
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis analysis aimed to characterize exceptional responder with long-term PARP inhibitor therapy (ExR-LT) in platinum-sensitive recurrent ovarian cancer.
methodsThis analysis included ExR-LT. ExR-LTs are defined as patients that received a continuous maintenance therapy for recurrent ovarian cancer with olaparib or niraparib for at least 5 years and showed an exceptional response. Exceptional response was defined as progression-free survival (PFS) of at least 5 years. This analysis has a retrospective and descriptive character.
results23 patients were included. The median duration of PARPi therapy was 7.1 years (range 5.3; 10.5). The longest treatment duration was reached in the BRCA1 mutation (BRCA1m) cohort with a mean duration of 8 years (range 5.3; 10.5 years). The majority of patients (16 patients, 69.7%) reported adverse events (AE) during PARPi therapy. 12 patients (52.2%) had mild AE (CTCAE 1 or 2), 4 patients (17.4%) reported more severe AE (CTCAE 3). 14 patients needed a dose reduction due to treatment-related AE (60.1%). The most common indications for dose reduction were anemia (17.4%), headache and limb pain (17.4%), and fatigue (13%). Four patients (17.4%) required an interruption of PARPi therapy. Ten patients received a dose reduction within the first 6 months and two patients after one and 1.3 years of PARPi therapy. No dose adjustments were necessary between 1.5 and 4 years. After 4 years, 3 patients (13%) received a late dose reduction. 8.6% had another cancer diagnosed before, 4.3% simultaneously, and 13% after the ovarian cancer diagnosis.
conclusionExR-LTs present with heterogenic clinical and genetic characteristics. Clinical management is complex because of a high rate of AE and need of dose reductions at various points in time. Close monitoring for AE, recurrences and secondary malignancies must be carried out throughout the entire time of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.